Impilo and KKR has entered into a strategic partnership together with management in Immedica Pharma

Impilo has entered into an agreement to divest (alongside the minority shareholders) its majority stake in Immedica Pharma, a pharmaceutical company focused on the commercialization of medicines for rare diseases and specialty care products, to KKR, a leading global investment firm.

In the transaction, Impilo will reinvest to become an equal owner alongside KKR, and the parties will work together with Immedica’s management team to support the Immedica’s continued growth. The transaction is subject to customary regulatory and closing conditions.

Immedica Pharma was established in 2018 by Impilo and an experienced management team. The business has built up a portfolio and pipeline of drugs, primarily within hematology and oncology as well as genetic and metabolic diseases for rare conditions with high unmet medical need, and has quickly expanded into an emerging leader in the European rare disease space, with revenues of EUR 100m and annual growth of more than 50%.

Mannheimer Swartling advised Impilo in the transaction.


This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.